Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/1993
10/20/1993EP0416108B1 Nutritious composition
10/20/1993EP0398925B1 Growth inhibiting agent and the use thereof
10/20/1993EP0220241B1 Purified protein having angiogenic activity and methods of preparation
10/19/1993US5254682 Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
10/19/1993US5254678 Ribozymes
10/19/1993US5254672 Synthetic peptides which contain sequences from factor VIIa, and the use thereof
10/19/1993US5254671 Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
10/19/1993US5254593 Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
10/19/1993US5254585 Use of peroxidized lipids for the preparation of a drug intended for the treatment of circulatory insufficiencies by local application
10/19/1993US5254579 N-(5-thioxo-L-prolyl)-L-cysteine, derivatives thereof, processes for the preparation thereof and pharmaceutical compositions containing them
10/19/1993US5254558 Treating respiratory system and cardiovascular disorders
10/19/1993US5254537 Composition and treatment with peptide combinations
10/19/1993US5254536 Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
10/19/1993US5254535 Composition and treatment with biologically active peptides and antibiotic
10/19/1993US5254534 Adjuvant for cancer immunotherapy
10/19/1993US5254532 Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
10/19/1993US5254350 Using a metal chelator
10/19/1993CA1323306C Pharmacological agent-lipid solution preparation
10/19/1993CA1323305C Delivery systems for pharmacological agents
10/19/1993CA1323303C Advanced anticancer therapy and cytotoxic medicaments for its implementation
10/19/1993CA1323302C Vaccine enhanced by interferon
10/19/1993CA1323301C Thyrotropin-releasing hormone analogs in cns injury
10/19/1993CA1323300C Thrombolytically active combination of pro-uk and uk
10/19/1993CA1323294C Method of treatment of central nervous system diseases such as alzheimer's disease and parkinson's disease and method of diagnosing alzheimer's disease
10/18/1993CA2094217A1 Transmucosal therapeutic composition
10/18/1993CA2094177A1 Derivatives of adipogenesis inhibitory factor, their preparation and their use
10/14/1993WO1993020439A1 Compositions and methods for regulating cellular signal transducing systems
10/14/1993WO1993020238A2 Amplification of human mdm2 gene in human tumors
10/14/1993WO1993020237A1 Homology cloning
10/14/1993WO1993020229A1 ANTIBODIES TO ALPHAvBETA3 INTEGRIN
10/14/1993WO1993020228A1 Novel, physiologically active protein and hemopoietic stem cell growth promoter
10/14/1993WO1993020210A1 Antibodies for treatment and prevention of respiratory syncytial virus infection
10/14/1993WO1993020207A1 Use of restriction endonucleases against viruses, including hiv
10/14/1993WO1993020204A1 Monomeric platelet-derived growth factor and prevention of stenosis or restenosis
10/14/1993WO1993020203A2 Stability-enhanced variants of parathyroid hormone
10/14/1993WO1993020202A1 Decorin fragments and methods of inhibiting cell regulatory factors
10/14/1993WO1993020201A1 GAP-ASSOCIATED PROTEIN p190 AND TRANSDUCTION
10/14/1993WO1993020200A1 Modified cells and method of treatment
10/14/1993WO1993020197A1 Stem cell proliferation factor
10/14/1993WO1993020196A1 Cloning, expression and uses of a novel secreted protein, f-spondin
10/14/1993WO1993020194A1 Tpa analog
10/14/1993WO1993020187A1 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
10/14/1993WO1993020108A1 Use of certain interferons for the treatment of disorders related to a misproportion of gamma-interferon producing t helper type 1 cells and interleukin-4 producing t helper type 2 cells
10/14/1993WO1993020107A1 Recombinant active forms of ecef, proteins that associate therewith, and uses thereof
10/14/1993WO1993020106A1 Protein cellular factor useful for regulating gene expression
10/14/1993WO1993020104A1 Monoclonal antibodies against a carbohydrate-dependent epitope related to the v2 region of hiv-1 gp120
10/14/1993WO1993020102A1 Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis
10/14/1993WO1993020101A1 Inhibitor of protein kinase c
10/14/1993WO1993020100A1 Novel lipophilic oligopeptides with immunomodulating activity
10/14/1993WO1993020099A2 Cck and/or gastrin receptor ligands
10/14/1993WO1993020095A1 Antisense oligonucleotide inhibition of papillomavirus
10/14/1993WO1993020093A1 Hybrid human/porcine factor viii
10/14/1993WO1993020076A1 Catalytic antibodies against cocaine and methods of using and producing same
10/14/1993WO1993020067A1 Benzodiazepine derivatives and protein and polypeptide conjugates thereof
10/14/1993WO1993019805A1 Fibrin sealant delivery method
10/14/1993WO1993019792A1 Aqueous peritoneal dialysis solution
10/14/1993WO1993019789A1 Wound dressing, wound plaster or carrier matrix
10/14/1993WO1993019786A1 High affinity, strongly neutralizing monoclonal antibodies against the cd-4 binding site of gp120 of human immunodeficiency virus
10/14/1993WO1993019785A1 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection
10/14/1993WO1993019784A1 Novel endothelial adhesion molecule for monocytes
10/14/1993WO1993019783A1 Methods of inhibiting or enhancing scar formation in the cns
10/14/1993WO1993019782A1 Specific detection of cell surface receptor leukocyte adhesion molecule-1
10/14/1993WO1993019780A1 Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a
10/14/1993WO1993019777A1 Fusion proteins comprising tumor necrosis factor receptor
10/14/1993WO1993019776A1 Protein formulation comprising growth hormone
10/14/1993WO1993019774A1 Amylin and possibly insulin containing composition for the treatment of anorexia and related states
10/14/1993WO1993019773A1 Lyophilized somatotropin formulations
10/14/1993WO1993019772A1 A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
10/14/1993WO1993019771A1 Pernasal preparation containing granulocyte colony-stimulating factor
10/14/1993WO1993019770A1 Compositions for the treatment of acute or chronic inflammation
10/14/1993WO1993019769A1 Wound healing and treatment of fibrotic disorders
10/14/1993WO1993019768A1 Self-assembling polynucleotide delivery system
10/14/1993WO1993019767A1 Cd28 pathway immunoregulation
10/14/1993WO1993019766A1 Methods and compositions for restoring impaired cellular immune function
10/14/1993WO1993019761A1 Lipid-a analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
10/14/1993WO1993019759A1 Vitamin d derivative feed compositions and methods of use
10/14/1993WO1993019740A1 Methods of manufacturing high dosage glutathione, the tablets and capsules produced thereby
10/14/1993WO1993019732A1 Skin care method and composition
10/14/1993WO1993019731A1 Skin care method and composition
10/14/1993WO1993019730A1 Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use
10/14/1993WO1993019605A1 Evaluation and treatment of patients with progressive immunosuppression
10/14/1993WO1993019591A1 Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
10/14/1993WO1993014208A3 Hepatitis e virus vaccine and method
10/14/1993WO1992008456A3 Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated
10/14/1993DE4211878A1 Compsn. for treating multiple sclerosis - comprising protein, peptide or aminoacid with low glycine, glutamine, glutamic acid, arginine and phenylalanine content
10/14/1993CA2133758A1 A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
10/14/1993CA2133737A1 Lyophilized somatotropin formulations
10/14/1993CA2133662A1 Antibodies for treatment and prevention of respiratory syncytial virus infection
10/14/1993CA2133569A1 Novel lipophilic oligopeptides with immunomodulating activity
10/14/1993CA2133443A1 Cloning, expression and uses of a novel secreted protein, f-spondin
10/14/1993CA2133193A1 Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use
10/14/1993CA2133085A1 Skin care method and composition
10/14/1993CA2133075A1 CD28 Pathway Immunoregulation
10/14/1993CA2132949A1 Stability-enhanced variants of parathyroid hormone
10/14/1993CA2132859A1 Decorin fragments and methods of inhibiting cell regulatory factors
10/14/1993CA2132624A1 Compositions and methods for regulating cellular signal transducing systems
10/14/1993CA2132516A1 Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis
10/14/1993CA2132341A1 Benzodiazepine derivatives and protein and polypeptide conjugates thereof
10/14/1993CA2126341A1 Lipid-a analogs: new monosaccharide and dissaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
10/14/1993CA2117495A1 Fibrin sealant delivery method
1 ... 2919 2920 2921 2922 2923 2924 2925 2926 2927 2928 2929 2930 2931 2932 2933 2934 2935 2936 2937 2938 2939 ... 3163